Merus NV
NASDAQ:MRUS
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22.86
60.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Merus NV
Merus NV
Operating Expenses
Merus NV
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Merus NV
NASDAQ:MRUS
|
Operating Expenses
-$266.9m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Operating Expenses
-$269.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-34%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Operating Expenses
-€48m
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Operating Expenses
-$196.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-15%
|
|
|
argenx SE
XBRU:ARGX
|
Operating Expenses
-$2.2B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-83%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Operating Expenses
-$46.5m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merus NV
Glance View
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 121 full-time employees. The company went IPO on 2016-05-19. The firm develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
See Also
What is Merus NV's Operating Expenses?
Operating Expenses
-266.9m
USD
Based on the financial report for Sep 30, 2024, Merus NV's Operating Expenses amounts to -266.9m USD.
What is Merus NV's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-30%
Over the last year, the Operating Expenses growth was -28%. The average annual Operating Expenses growth rates for Merus NV have been -26% over the past three years , -30% over the past five years .
You don't have any saved screeners yet
